title: Rattle-structured multifunctional nanotheranostics for synergetic chemo-/radiotherapy and simultaneous magnetic/luminescent dual-mode imaging.
abstract: Most hypoxic tumors are insensitive to radiation, which is a major obstacle in the development of conventional radiotherapy for tumor treatment. Some drugs, such as cisplatin (CDDP), have been extensively used both as an anticancer drug and clinically as a radiosensitizer to enhance radiotherapy. Herein, we develop rattle-structured multifunctional up-conversion core/porous silica shell nanotheranostics (UCSNs) for delivering CDDP to tumors for synergetic chemo-/radiotherapy by CDDP radiosensitization and magnetic/luminescent dual-mode imaging. UCSNs had a dynamic light scattering diameter of 79.1 nm and excellent water dispersity and stability. In vitro studies showed that CDDP loaded in UCSNs (UCSNs-CDDP) was more effective than free CDDP as a radiosensitizer. After injection, UCSNs-CDDP also demonstrated unambiguously enhanced radiotherapy efficacy in vivo. Our report aims at presenting a novel strategy in biomedical nanotechnology that allows simultaneous dual-mode imaging and localized therapy via synergetic chemo-/radiotherapy, which may achieve optimized therapeutic efficacy in cancer treatment.
authors.affiliation: State Key Laboratory of High Performance Ceramics and Superfine Microstructures, Shanghai Institute of Ceramics, Chinese Academy of Sciences, 1295 Ding-xi Road, Shanghai 200050, P.R. China.
authors.forename: Wenpei
authors.initials: W
authors.lastname: Fan
authors.forename: Bo
authors.initials: B
authors.lastname: Shen
authors.forename: Wenbo
authors.initials: W
authors.lastname: Bu
authors.forename: Feng
authors.initials: F
authors.lastname: Chen
authors.forename: Kuaile
authors.initials: K
authors.lastname: Zhao
authors.forename: Shengjian
authors.initials: S
authors.lastname: Zhang
authors.forename: Liangping
authors.initials: L
authors.lastname: Zhou
authors.forename: Weijun
authors.initials: W
authors.lastname: Peng
authors.forename: Qingfeng
authors.initials: Q
authors.lastname: Xiao
authors.forename: Huaiyong
authors.initials: H
authors.lastname: Xing
authors.forename: Jianan
authors.initials: J
authors.lastname: Liu
authors.forename: Dalong
authors.initials: D
authors.lastname: Ni
authors.forename: Qianjun
authors.initials: Q
authors.lastname: He
authors.forename: Jianlin
authors.initials: J
authors.lastname: Shi
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002470:Cell Survival; D059248:Chemoradiotherapy / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D004396:Coloring Agents; D003287:Contrast Media; D016503:Drug Delivery Systems; D005682:Gadolinium; D006367:HeLa Cells; D006801:Humans; D008027:Light; D049449:Luminescence; D008279:Magnetic Resonance Imaging / Q000379:methods*; D018613:Microscopy, Confocal; D046529:Microscopy, Electron, Transmission; D053758:Nanoparticles; D036103:Nanotechnology; D009369:Neoplasms / Q000473:pathology* / Q000628:therapy*; D010316:Particle Size; D016062:Porosity; D012542:Scattering, Radiation; D013778:Tetrazolium Salts; D013844:Thiazoles
chemical_list: D000970:Antineoplastic Agents; D004396:Coloring Agents; D003287:Contrast Media; D013778:Tetrazolium Salts; D013844:Thiazoles; D005682:Gadolinium; C022616:thiazolyl blue; D002945:Cisplatin